

oncology pipeline

IMMUNO-ONCOLOGY


Assets

View More

Avelumab

anti-PD-L1 mAb


Development Phase I III



Bintrafusp alfa

TGF- β "trap"/anti-PD-L1


Development Phase II



M6223

anti-TIGIT mAb

Development Phase I



DNA DAMAGE RESPONSE (DDR)

Assets

View More

Peposertib (M3814)

DNA-PK inhibitor


Development Phase I



Berzosertib (M6620)

ATR inhibitor

Development Phase I II



M1774

ATR inhibitor

Development Phase I



M4076

ATM inhibitor

Development Phase I



ONCOGENIC PATHWAYS

Assets

View More

Tepotinib

MET kinase inhibitor


Development Phase II



Xevinapant

Antagonist of inhibitor of apoptosis proteins (IAPs)


Development Phase III



M1231

Anti-EGFR and MUC1 ADC

Development Phase I



Updated: November 2021

The Healthcare business of Merck KGaA, Darmstadt, Germany operates as EMD Serono in the United States and Canada.

Pipeline compounds are being investigated for the treatment of various diseases. Efficacy and safety of these compounds are still under investigation in various indications. Regulatory approval is dependent on the completion of the study programs and review by local regulatory authorities, and varies from country to country. Clinical trial information is available at www.clinicaltrials.gov.


**EMD
SERONO**

US-MULOP-00036 | November 2021

oncology pipeline

BACK

IMMUNO-ONCOLOGY >



1L, first-line treatment; 2L, second-line treatment.

¹Avelumab is being co-developed and co-marketed by Merck Healthcare KGaA, Darmstadt, Germany and Pfizer Inc.

The Healthcare business of Merck KGaA, Darmstadt, Germany operates as EMD Serono in the United States and Canada.

Pipeline compounds are being investigated for the treatment of various diseases. Efficacy and safety of these compounds are still under investigation in various indications. Regulatory approval is dependent on the completion of the study programs and review by local regulatory authorities, and varies from country to country. Clinical trial information is available at www.clinicaltrials.gov.

**EMD
SERONO**

US-MULOP-00036 | November 2021

DNA DAMAGE RESPONSE (DDR) >

	TREATMENT	TUMOR SETTING	DEVELOPMENT PHASE		
			I	II	III
peposertib (M3814) DNA-PK inhibitor Learn More >	Combination with capecitabine and radiotherapy	Rectal cancer			
	Combination with avelumab and/or radiotherapy	Solid tumors			
	Combination with cisplatin and radiotherapy	Solid tumors			
berzosertib (M6620) ATR inhibitor Learn More >	Combination with chemotherapy and/or radiotherapy	Solid tumors			
		SCLC			
M1774 ATR inhibitor Learn More >	Monotherapy and combination with niraparib	Solid tumors			
M4076 ATM inhibitor Learn More >	Monotherapy	Solid tumors			

ONCOGENIC PATHWAYS >

